[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Matei DV, Rocco B, Varela R, Verweij F, Scardino E, Renne G, De Cobelli O: Synchronous collecting duct carcinoma and papillary renal cell carcinoma: a case report and review of the literature. Anticancer Res; 2005 Jan-Feb;25(1B):579-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous collecting duct carcinoma and papillary renal cell carcinoma: a case report and review of the literature.
  • The coexistence of multiple and synchronous primary neoplasms in the same organ (including kidney) has only rarely been described in the literature.
  • We herein present a case of collecting duct carcinoma (CDC) combined with papillary renal carcinoma (RCC) having a 57-month disease-free survival CDC is a rather rare and aggressive neoplasm of the kidney.
  • Sharing probably the same embryological origin, synchronous or metachronous association with in situ orpapillary transitional cell carcinoma (TCC) may be found; association with RCC has been only once reported in the literature.
  • The high incidence of c-erbB-2 oncogene amplification in CDC further characterizes this tumor as a separate entity from renal cell carcinoma, and shows some genetic characteristics in common with TCC.
  • The histological diagnosis of Bellini CDC can be confirmed by the positive immunohistochemical staining with a collecting duct marker and distal tubule marker and negative staining with a proximal tubule marker.
  • [MeSH-major] Carcinoma / complications. Carcinoma / diagnosis. Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Kidney Tubules, Collecting / pathology
  • [MeSH-minor] Aged. Disease-Free Survival. Humans. Immunohistochemistry. Kidney / pathology. Male. Neoplasms, Multiple Primary / diagnosis. Receptor, ErbB-2 / biosynthesis. Time Factors. Tomography, X-Ray Computed


2. Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, Haacke EM: Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors. Neoplasia; 2009 Sep;11(9):910-20
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.
  • To investigate further the antiangiogenic potential of sunitinib for renal cell carcinoma (RCC) treatment, its effects on tumor vasculature were monitored by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using an orthotopic KCI-18 model of human RCC xenografts in nude mice.
  • Sunitinib induced dose-dependent vascular changes, which were observed both in kidney tumors and in normal kidneys by DCE-MRI.
  • A dosage of 10 mg/kg per day caused mild changes in Gd uptake and clearance kinetics in kidney tumors.
  • However, sunitinib at 20 mg/kg per day caused increased tumor perfusion and decreased vascular permeability associated with thinning and regularization of tumor vessels while mildly affecting normal vessels as confirmed by histologic diagnosis.
  • KCI-18 cells and tumors expressed vascular endothelial growth factor receptor 2 and platelet-derived growth factor receptor beta molecular targets of sunitinib that were modulated by the drug treatment.
  • These data suggest that a sunitinib dosage of 20 mg/kg per day, which inhibits RCC tumor growth and regularizes tumor vessels with milder effects on normal vessels, could be used to improve blood flow for combination with chemotherapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Capillary Permeability / drug effects. Carcinoma, Renal Cell / blood supply. Carcinoma, Renal Cell / drug therapy. Indoles / pharmacology. Neovascularization, Pathologic / prevention & control. Pyrroles / pharmacology
  • [MeSH-minor] Animals. Anoxia. Contrast Media. Female. Gadolinium DTPA. Humans. Immunoprecipitation. Kidney Neoplasms / blood supply. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Magnetic Resonance Imaging. Mice. Mice, Inbred BALB C. Mice, Nude. Receptors, Platelet-Derived Growth Factor / metabolism. Tumor Cells, Cultured. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):463-72 [17763352.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5565-70 [11034104.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1655-9 [11759643.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):727-39 [12360276.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):327-37 [12538485.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3188-97 [12515727.001]
  • [Cites] Blood. 2003 May 1;101(9):3597-605 [12531805.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):471-8 [12748309.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17069-74 [17942672.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Mar;61(3):515-24 [17505827.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2011-9 [18083403.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Neoplasia. 2008 Apr;10(4):354-62 [18392132.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1810-6 [18347007.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3743-8 [18669461.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1613-8 [18436521.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4572-8 [18824708.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5204-12 [18838713.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3584-90 [19487381.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1979-86 [12799646.001]
  • [Cites] Mol Cancer Ther. 2003 Oct;2(10):1011-21 [14578466.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1889-95 [14612898.001]
  • [Cites] Clin Exp Metastasis. 2003;20(8):757-66 [14713109.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]
  • [Cites] N Engl J Med. 1996 Sep 19;335(12):865-75 [8778606.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5711-9 [15994946.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5827-32 [16115922.001]
  • [Cites] Urology. 2005 Nov;66(5 Suppl):1-9 [16194700.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3293-8 [16829653.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Magn Reson Imaging. 2007 Jan;25(1):1-13 [17222711.001]
  • [Cites] BMC Cancer. 2007;7:4 [17212824.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2141-9 [17332344.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3449-59 [17575207.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):R15-24 [10772661.001]
  • (PMID = 19724685.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2735805
  •  go-up   go-down


3. Inagaki T, Hagino K, Matsumura N, Koh M, Nishikawa T, Suzuki A, Hirano A, Shinka T: [A case of collecting duct carcinoma (Bellini duct carcinoma) producing carcinoembryonic antigen]. Hinyokika Kiyo; 2001 Mar;47(3):183-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of collecting duct carcinoma (Bellini duct carcinoma) producing carcinoembryonic antigen].
  • We report a case of collecting duct carcinoma (Bellini duct carcinoma) producing carcinoembryonic antigen (CEA).
  • Computed tomography showed a low density tumor measuring about 3 cm in the left kidney.
  • Histological examination revealed collecting duct carcinoma with papillary growth (T1aN1M0).
  • Under a diagnosis of CEA-producing collecting duct carcinoma of the left kidney, the patient underwent systemic chemotherapy (M-VAC).
  • The serum level of CEA decreased to the normal level after the nephrectomy, but six months postoperatively, metastatic bone tumor at the left pelvic bone was revealed on the plain film and at the same time, the CEA level was increased again.
  • [MeSH-major] Carcinoembryonic Antigen / biosynthesis. Carcinoma, Papillary / pathology. Kidney Neoplasms / pathology. Kidney Tubules, Collecting
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Nephrectomy. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11329960.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


Advertisement
4. Barama A, St-Louis G, Nicolet V, Hadjeres R, Daloze P: Renal cell carcinoma in kidney allografts: a case series from a single center. Am J Transplant; 2005 Dec;5(12):3015-8
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma in kidney allografts: a case series from a single center.
  • In kidney transplant recipients, renal cell carcinoma (RCC) occurs either in the native kidney or, less frequently, in the grafted kidney.
  • Here, we report a series of rare cases involving 5 patients from a single center who developed RCC in their grafts.
  • The diagnosis was made serendipitously by ultrasound.
  • The time lapse post-transplant varied from 4 to 17 years.
  • Surgical treatment consisted of nephron-sparing surgery (NSS) in four cases and a secondary radical nephrectomy in one case.
  • The histopathology was clear cell type in four cases and papillary RCC in one case.
  • Patients treated by NSS retained kidney function for 2 years or more, and none of them presented early neoplasia recurrence.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Carcinoma, Renal Cell / ultrasonography. Kidney Neoplasms / surgery. Kidney Neoplasms / ultrasonography. Kidney Transplantation
  • [MeSH-minor] Adult. Female. Graft Rejection / drug therapy. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Nephrectomy / methods. Postoperative Complications / surgery. Postoperative Complications / ultrasonography. Transplantation, Homologous

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16303018.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


5. Wolff EF, Hughes M, Merino MJ, Reynolds JC, Davis JL, Cochran CS, Celi FS: Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer. Thyroid; 2010 Sep;20(9):981-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer.
  • BACKGROUND: The most common type of ovarian germ cell tumor is the teratoma.
  • Thyroid tissue, both benign and malignant, may be a component of an ovarian teratoma.
  • SUMMARY: Malignant thyroid tissue is often difficult to distinguish from benign thyroid tissue arising in ovarian teratomas.
  • Postoperatively, tumor tissue should be referred to pathologists experienced with differentiating benign from malignant struma ovarii.
  • Once diagnosed, treatment of this rare condition should be handled by a team of specialists with combined treatment modalities.
  • We cared for woman with disseminated thyroid cancer arising in an ovarian teratoma whose history illustrates the complexity of managing ovarian teratomas with malignant thyroid tissue.
  • During her next pregnancy, pelvic masses were noted; biopsies revealed well-differentiated papillary thyroid carcinoma, follicular variant.
  • A post-(131)I treatment scan revealed diffuse uptake throughout the abdomen.
  • She then developed abdominal pain and, on computed tomography, was found to have multiple intraabdominal foci of disease.
  • A 18 fluorodeoxyglucose positron emission tomography scan showed no pathological uptake.
  • CONCLUSIONS: Aggressive multimodal management appears to be the most promising approach for malignant thyroid tissue arising in ovarian teratomas.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LITHIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2009 Jun 18;360(25):2680-1; author reply 2682-3 [19537322.001]
  • [Cites] Endocr Pract. 2009 Mar;15(2):167-73 [19289330.001]
  • [Cites] Histopathology. 2009 Oct;55(4):482-7 [19817905.001]
  • [Cites] Endocr Pathol. 2010 Jun;21(2):144-7 [19898969.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):225-6 [10785468.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3512-5 [11502772.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):575-7 [11520159.001]
  • [Cites] Gynecol Oncol. 2002 Aug;86(2):231-4 [12144834.001]
  • [Cites] J Reprod Med. 2003 Jan;48(1):52-6 [12611097.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):226-8 [15262148.001]
  • [Cites] Clin Nucl Med. 1988 Dec;13(12):866-8 [3246114.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jul;69(1):186-90 [2499590.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):143-6 [7901063.001]
  • [Cites] Int J Gynecol Pathol. 1993 Oct;12(4):333-43 [8253550.001]
  • [Cites] Pathol Res Pract. 1994 Nov;190(11):1082-5; discussion 1086-8 [7746743.001]
  • [Cites] Histopathology. 1997 Sep;31(3):289-90 [9354902.001]
  • [Cites] J Postgrad Med. 1996 Apr-Jun;42(2):39-42 [9715297.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):912-6 [10084570.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):282-4 [15790478.001]
  • [Cites] Curr Opin Obstet Gynecol. 2005 Jun;17(3):299-308 [15870565.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):694-7 [16021577.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1156-9 [16343201.001]
  • [Cites] Thyroid. 2005 Dec;15(12):1355-61 [16405408.001]
  • [Cites] Pathology. 2007 Feb;39(1):139-46 [17365830.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):321-4 [17240432.001]
  • [Cites] Int J Surg Pathol. 2007 Apr;15(2):116-20 [17478764.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1337-43 [17721188.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):182-6 [18058267.001]
  • [Cites] Clin Nucl Med. 2008 Apr;33(4):247-50 [18356660.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):213-22 [18317221.001]
  • [Cites] Gynecol Endocrinol. 2008 Jun;24(6):312-9 [18584410.001]
  • [Cites] Ultrasound Obstet Gynecol. 2008 Aug;32(2):210-9 [18636616.001]
  • [Cites] Ceylon Med J. 2008 Jun;53(2):55-6 [18678124.001]
  • [Cites] Int J Gynecol Pathol. 2008 Oct;27(4):496-506 [18753973.001]
  • [Cites] Obstet Gynecol Surv. 2008 Nov;63(11):725-32 [18928577.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Apr 1;190(1):15-20 [19264228.001]
  • [Cites] Thyroid. 2009 Oct;19(10):1093-8 [19732012.001]
  • (PMID = 20718682.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Isotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin; 9FN79X2M3F / Lithium; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; Q51BO43MG4 / Thyroxine
  • [Other-IDs] NLM/ PMC2964358
  •  go-up   go-down


6. Morikawa H, Yamada Y, Oda H, Kitahara K, Kanemura M, Komatsu H, Kawagoe S: [A case of Bellini duct carcinoma producing granulocyte colony-stimulating factor (G-CSF)]. Hinyokika Kiyo; 2001 Jul;47(7):485-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Bellini duct carcinoma producing granulocyte colony-stimulating factor (G-CSF)].
  • A case of Bellini duct carcinoma producing granulocyte colony-stimulating factor (G-CSF) is reported.
  • Abdominal ultrasonography and abdominal computed tomography revealed left renal pelvic tumor.
  • The histopathological report showed Bellini duct carcinoma.
  • In spite of chemotherapy, she died of brain metastases 7 months after the operation.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Granulocyte Colony-Stimulating Factor / biosynthesis. Kidney Neoplasms / diagnosis. Kidney Tubules, Collecting

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11523133.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Number-of-references] 7
  •  go-up   go-down


7. Takase Y, Kohno M, Kobayashi T, Tokunaga S, Imamura Y: [Bellini duct carcinoma: a case report]. Hinyokika Kiyo; 2004 Jun;50(6):425-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bellini duct carcinoma: a case report].
  • A 53-year-old man was admitted to our hospital for the extensive examination and treatment of suspicioun of right renal pelvic tumor.
  • Retrograde pyelography (RP), computed tomography (CT) and magnetic resonance imaging (MRI) showed a space-occupying lesion, about 2 cm in diameter, spread from the renal parenchyma to the renal pelvis.
  • Right nephroureterectomy was performed because transitional cell carcinoma was suspected from the histopothology of the frozen section.
  • Histological examination showed Bellini duct carcinoma of the papillary type.
  • He received adjuvant combination chemotherapy with M-VAC (Methotrexate, vinblastine, doxorubicin, cisplatin).
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Kidney Tubules, Collecting
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15293743.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 8
  •  go-up   go-down


8. Liu LN, Chen GY, Wang P, Zhang CH, Huang SF: [Papillary renal cell carcinoma: clinico-pathologic studies of 33 cases]. Zhonghua Zhong Liu Za Zhi; 2005 Feb;27(2):102-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papillary renal cell carcinoma: clinico-pathologic studies of 33 cases].
  • OBJECTIVE: To investigate the morphologic features, differential diagnosis, prognosis and histogenesis of papillary renal cell carcinoma (PRCC).
  • Light microscopic observation, immunohistochemical assay of EMA, CK7, CD10, Vim, 34 beta E12 by tissue chip were performed.
  • Besides typical papillae, inconspicuous papillary patterns, such as trabecular, tubular, micronodular and pseudostratified patterns could be seen.
  • Tumors were of two major types: basophilic type (n = 10), with small cuboid cell and pale cytoplasm (n = 10), 9 of them were low in Fuhrman grading; eosinophilic type (n = 22) with large columnar cells, rich in eosinophilic cytoplasm, 19 of them were high in Fuhrman grading.
  • The remaining case was of clear cell type.
  • The basophilic tumors were all positive for distal tubule marker EMA/CK7, none for proximal tubule marker CD10, 7 tumors positive for Vim.
  • The prognosis of PRCC was worse than that of chromophobe renal cell carcinoma.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Keratin-7. Keratins / metabolism. Kidney Tubules / metabolism. Male. Middle Aged. Mucin-1 / metabolism. Neprilysin / metabolism. Survival Rate. Vimentin / metabolism

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946550.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


9. Ryu DR, Yoo TH, Kim YT, Jeong HJ, Cho NH, Kang SW: Minimal change disease in a patient with ovarian papillary serous carcinoma. Gynecol Oncol; 2004 May;93(2):554-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal change disease in a patient with ovarian papillary serous carcinoma.
  • Only five cases of NS with pathologic diagnosis have been reported in patients with ovarian tumors.
  • Histopathology of the mass and the kidney revealed papillary serous carcinoma of the ovary and MCD, respectively.
  • Oral prednisolone and adjuvant chemotherapy resulted in remission of NS.
  • CONCLUSION: We herein report a case of MCD associated with ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Papillary / complications. Cystadenocarcinoma, Serous / complications. Nephrosis, Lipoid / complications. Ovarian Neoplasms / complications

  • Genetic Alliance. consumer health - Minimal change disease.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15099980.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Sagristani M, Caraglia M, Villa MR, Lucania A, Esposito M, Petriccione L, Improta S, Marra M, Iannaci G, Rossiello R, Mastrullo L: Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer. J Exp Clin Cancer Res; 2007 Jun;26(2):291-2
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer.
  • In this manuscript for the first time we describe the concomitant diagnosis of primary renal non-Hodgkin lymphoma (PRL) and of a papillary urothelial cancer in a patient with megaloblastic anemia.
  • PRL is a rare disease, since the kidney is one of the extranodal organs usually not containing lymphoid tissue.
  • A review of literature indicated that simultaneous diagnosis of PRL and papillary urothelial carcinoma of the urether, makes our case unique.
  • The early diagnosis of both diseases allowed the eradication of the two neoplasms by nephro-ureterecthomy and by performing subsequent systemic chemotherapy.
  • [MeSH-major] Carcinoma, Papillary / radiography. Kidney Neoplasms / radiography. Lymphoma, Non-Hodgkin / radiography. Ureteral Neoplasms / radiography
  • [MeSH-minor] Early Diagnosis. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725112.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Liu W, Tretiakova M, Kong J, Turkyilmaz M, Li YC, Krausz T: Expression of vitamin D3 receptor in kidney tumors. Hum Pathol; 2006 Oct;37(10):1268-78
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of vitamin D3 receptor in kidney tumors.
  • The kidney is not only a primary vitamin D target organ but also is a key site of vitamin D metabolism.
  • Our preliminary immunohistochemical study showed that vitamin D receptor (VDR) was highly expressed in renal distal tubules and collecting ducts, whereas the renal proximal tubules and glomeruli did not express VDR.
  • These observations led us to study the expression of VDR in various kidney tumors to determine the possible diagnostic utility of VDR.
  • Paraffin tissue microarray (TMA) blocks were constructed containing core cylinders from clear cell (52), papillary (35), chromophobe (20), sarcomatoid (20), and metastatic (59) renal cell carcinomas (RCCs).
  • Furthermore, VDR messenger RNA and protein expression was also quantified using real-time reverse transcriptase-polymerase chain reaction and Western blot analysis.
  • Vitamin D receptor was strongly positive in collecting duct carcinomas (100% [3/3], cytoplasmic), papillary RCCs (94% [33/35], cytoplasmic), chromophobe RCCs (85% [17/20], membranous), and oncocytomas (90% [18/20], cytoplasmic with perinuclear accentuation).
  • Vitamin D receptor was weakly positive in sarcomatoid variant RCCs (88% [14/16]) regardless of the type of associated original RCC.
  • The preferential expression of VDR in chromophobe RCCs, oncocytomas, and collecting duct carcinomas is in agreement with the concept that these tumors differentiate toward epithelium lining the distal convoluted tubules and collecting ducts.
  • In addition, the focal and much weaker VDR expression in clear cell RCCs makes VDR valuable in distinguishing clear cell RCC from other types of RCCs.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Receptors, Calcitriol / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Gene Expression. Humans. Immunoenzyme Techniques. Male. Middle Aged. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949927.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Calcitriol
  •  go-up   go-down


12. Holmäng S, Thomsen J, Johansson SL: Micropapillary carcinoma of the renal pelvis and ureter. J Urol; 2006 Feb;175(2):463-6; discussion 466-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary carcinoma of the renal pelvis and ureter.
  • Median patient age at diagnosis was 69 years (range 54 to 88) and the male-to-female ratio was 17:9.
  • Carcinoma in situ was identified in 64% of cases and vascular invasion was present in 81%.
  • Stage for stage the prognosis is not different from that in nonMPC urothelial cell carcinoma.
  • However, radiotherapy and systemic chemotherapy appear to be ineffective.
  • [MeSH-major] Carcinoma, Papillary. Kidney Neoplasms. Kidney Pelvis. Ureteral Neoplasms

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406972.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Okoń K: Pathology of renal tumors in adults. Molecular biology, histopathological diagnosis and prognosis. Pol J Pathol; 2008;59(3):129-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of renal tumors in adults. Molecular biology, histopathological diagnosis and prognosis.
  • Since the fifties, the incidence of renal cancers has been increasing, but at the some time the prognosis has been improving.
  • In particular, in the last years, several new treatment modalities have been introduced, relying on the understanding of renal cancer biology.
  • There are several renal tumor types differing in morphology, molecular genetics and biology.
  • Inactivation of the VHL gene leads to formation of the most frequent form in adults, namely clear cell carcinoma.
  • Papillary carcinomas depend mainly on the HGF receptor gene (c-Met) activating mutations.
  • At least two types of papillary carcinomas exist, which have different morphology and prognosis.
  • The molecular biology of chromophobe carcinoma and oncocytoma is poorly understood.
  • Differential diagnosis of these tumors is particularly difficult and may require extensive immunohistochemical and molecular studies.
  • Collecting duct carcinoma and medullary carcinoma are extremely aggressive but rare tumors.
  • Some renal tumors have been described or recognized only relatively recently; these newer entities include multilocular cystic clear cell carcinoma, spindle cell papillary mucinous carcinoma, tubulocystic carcinoma, renal epithelial and stromal tumor, epithelioid and oncocytic angiomyolipoma.
  • The improved prognosis in renal cancer depends on earlier detection, but also on refinement of therapeutic methods.
  • Renal carcinoma is notorious for its low sensitivity to chemotherapy and radiotherapy.
  • For several years, immunological treatment with IL-2 and INF-alpha was the only adjuvant therapy method.
  • However, recently several new drugs have been introduced; they act on tyrosine-kinase receptors, VEGF, c-Met or mTOR pathway.
  • With this progress, perfect understanding of renal tumor biology and exact histological diagnosis have become of prime practical importance.
  • [MeSH-major] Kidney Neoplasms


14. Refae MA, Wong N, Patenaude F, Bégin LR, Foulkes WD: Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma. Nat Clin Pract Oncol; 2007 Apr;4(4):256-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma.
  • After an initial biopsy of the neck mass, which revealed metastatic carcinoma, a left radical nephrectomy was performed as well as excision of a left supraclavicular lymph node.
  • Subsequent inquiry revealed that the patient's father had died of metastatic renal cell carcinoma (RCC) at the age of 40 years, and that other family members had also developed skin and uterine leiomyomas.
  • DIAGNOSIS: Papillary type 2 RCC described in the context of hereditary leiomyomatosis and renal cell cancer (HLRCC), an autosomal dominant syndrome attributable to a mutation in the fumarate hydratase (FH) gene on chromosome 1.
  • MANAGEMENT: Radical nephrectomy, immunotherapy, chemotherapy and repeat surgical debulking.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Leiomyomatosis / genetics
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Fumarate Hydratase / genetics. Humans. Male. Mutation


15. Toma V, Zuber C, Sata T, Komminoth P, Hailemariam S, Eble JN, Heitz PU, Roth J: Thomsen-Friedenreich glycotope is expressed in developing and normal kidney but not in renal neoplasms. Hum Pathol; 2000 Jun;31(6):647-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thomsen-Friedenreich glycotope is expressed in developing and normal kidney but not in renal neoplasms.
  • The Thomsen-Friedenreich glycotope (TF) is considered a general carcinoma autoantigen and is therefore of importance in cancer diagnosis and immunotherapy.
  • We report the distribution of the TF glycotope in developing and adult human kidney and renal neoplasms.
  • In developing kidney, the TF was restricted to the loop of Henle, distal tubules, and peripheral collecting ducts, whereas its sialylated form was detectable in all epithelial differentiations derived from the 2 embryonic anlagen, the metanephrogenic blastema being unreactive.
  • This pattern was essentially preserved in adult kidney, with TF labeling beginning in the thick ascending limb and extending into the collecting ducts of outer medulla.
  • Analysis of a spectrum of renal neoplasms failed to detect the TF, with the exception of occasional staining of tubules in nephroblastoma.
  • Moreover, the sialylated TF was only detectable in oncocytoma, chromophobe renal cell carcinoma, cystic nephroma, nephroblastoma, and nephroblastomatosis complex and occasionally in type 1 papillary renal cell carcinoma.
  • Thus, the TF and its sialylated form are expressed in normal developing and adult kidney.
  • However, the TF does not seem to represent a tumor-associated glycotope in human kidney, nor does it appear to be of value in diagnosis and immunotherapy of renal neoplasms.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Kidney / immunology. Kidney Neoplasms / immunology. Plant Lectins

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10872656.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Coloring Agents; 0 / Lectins; 0 / Plant Lectins; 0 / amaranthin protein, Amaranthus; 3554-90-3 / Thomsen-Friedenreich antigen; EC 3.2.2.22 / Ribosome Inactivating Proteins; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


16. Nishio S, Kawata T, Harada C, Kawagoe H, Fujiyoshi K, Ishimatsu J, Tsunawaki A, Sugiyama T, Kamura T: [A case of extraovarian primary peritoneal carcinoma successfully treated with weekly paclitaxel]. Gan To Kagaku Ryoho; 2002 Feb;29(2):309-12
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of extraovarian primary peritoneal carcinoma successfully treated with weekly paclitaxel].
  • We report the use of paclitaxel in the successful treatment of a 74-year-old patient with extraovarian primary peritoneal carcinoma and acute renal failure caused by intraperitoneal cisplatin.
  • The histological diagnosis was papillary serous adenocarcinoma.
  • She showed a clinical response after three cycles, and then underwent secondary cytoreductive surgery after which she received one additional cycle of therapy.
  • She enjoyed a favorable quality of life without evidence of disease for 16 months after the completion of this therapy.
  • Weekly 1-hour paclitaxel (70 mg/m2) was well tolerated, yet was effective for extraovarian primary peritoneal carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Cystadenocarcinoma, Papillary / drug therapy. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Aged. Cisplatin / adverse effects. Drug Administration Schedule. Female. Humans

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11865640.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Kafé H, Verbavatz JM, Cochand-Priollet B, Castagnet P, Vieillefond A: Collecting duct carcinoma: an entity to be redefined? Virchows Arch; 2004 Dec;445(6):637-40
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collecting duct carcinoma: an entity to be redefined?
  • Collecting duct carcinomas (CDCs) are highly aggressive tumors with poor survival at 1 year and are often metastatic at the time of diagnosis.
  • It has been shown that patients may have better survival when treated with a chemotherapy regimen used for urothelial carcinoma.
  • Such tumors must therefore be recognized, but their pathological diagnosis remains difficult.
  • The two main differential diagnoses are renal pelvis urothelial carcinoma with infiltration of the kidney and/or high-grade and high-stage papillary renal cell carcinoma.
  • In contrast, the 4 remaining papillary CDCs had the inverse pattern, AQP-3-, vimentin+ and UEA-.
  • (2) the papillary variant probably does not belong to the same entity;.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Tubules, Collecting

  • Genetic Alliance. consumer health - Collecting Duct Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Renal Physiol. 2000 Jan;278(1):F13-28 [10644652.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Science. 1992 Apr 17;256(5055):385-7 [1373524.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):111-6 [11815966.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1138-40 [14501710.001]
  • [Cites] J Biol Chem. 1998 Apr 3;273(14):8407-12 [9525951.001]
  • [Cites] Am J Physiol. 1995 Nov;269(5 Pt 2):F663-72 [7503232.001]
  • [Cites] Histopathology. 1985 Oct;9(10):1037-50 [2417930.001]
  • [Cites] Histopathology. 1991 Feb;18(2):115-22 [1707029.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):54-67 [9503506.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):449-56 [2318486.001]
  • (PMID = 15480763.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AQP3 protein, human; 0 / Aquaporins; 0 / Vimentin; 158801-98-0 / Aquaporin 3
  •  go-up   go-down


18. Kuroda N, Guo L, Toi M, Naruse K, Miyazaki E, Hayashi Y, Yoshikawa C, Ashida S, Shuin T, Enzan H: Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma. Appl Immunohistochem Mol Morphol; 2001 Dec;9(4):315-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma.
  • In this study, 91 renal tumors--65 conventional renal cell carcinomas (RCCs), 14 papillary RCCs, 6 chromophobe RCCs, 4 collecting duct carcinomas, 2 oncocytomas--were investigated for the immunohistochemical expression of paxillin.
  • In a normal kidney, paxillin was predominantly expressed in the cytoplasm of distal tubules, loops of Henle, collecting ducts, and vascular smooth muscle cells.
  • In contrast to these tumors, conventional RCCs, papillary RCCs, and collecting duct carcinomas showed negative reactions for paxillin except for one case in each subgroup with weak reactivity.
  • An immunoblot analysis confirmed the presence of paxillin in healthy kidney, chromophobe RCC, and oncocytoma.
  • In addition, paxillin may be an available marker in distinguishing chromophobe RCCs from conventional or papillary RCCs.

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11759057.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Neoplasm Proteins; 0 / PXN protein, human; 0 / Paxillin; 0 / Phosphoproteins
  •  go-up   go-down


19. Pan CC, Chen PC, Ho DM: The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology; 2004 Nov;45(5):452-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases.
  • AIMS: To demonstrate the diagnostic utility of MOC31, BerEP4, renal cell carcinoma marker (RCC Ma) and CD10 in the classification of RCC and renal oncocytoma, based upon a comprehensive immunohistochemical analysis.
  • METHODS AND RESULTS: Immunohistochemistry was performed on 328 samples consisting of 256 clear cell/conventional, 27 papillary, 28 chromophobe, five collecting duct, five unclassified RCCs and seven renal oncocytomas using antibodies MOC31, BerEP4 and antibodies against cytokeratins (KL-1, CAM5.2, 34betaE12, cytokeratin 7), RCC Ma, epithelial membrane antigen, E-cadherin, CD10, CD15 and vimentin.
  • MOC31 and BerEP4 chiefly labelled distal tubules of normal kidney while RCC Ma and CD10 labelled the proximal tubules.
  • Twenty-three chromophobe RCCs (82%) were reactive for MOC31, while only four clear cell RCCs and three papillary RCCs were positive for this marker.
  • Papillary RCCs frequently coexpressed RCC Ma and BerEP4 (51%).
  • The CD10+/BerEP4- profile and RCC Ma+/BerEP4+ profile achieve moderate sensitivity and good specificity for clear cell RCC and papillary RCC, respectively.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Biomarkers, Tumor. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Mitogen-Activated Protein Kinases. Neprilysin

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15500648.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125; EC 2.7.11.22 / MOK protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


20. Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R, Rubinstein L, Sausville EA, Vistica DT: Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1. J Urol; 2004 Apr;171(4):1688-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.
  • We identified cellular correlates of responsiveness to AF in continuous human tumor renal cell carcinoma lines and in tumor cell isolates, termed renal carcinoma cell strains, from patients with clear cell and papillary renal neoplasms.
  • In vivo antitumor activity of the drug was determined in mice bearing xenografts.
  • In vivo treatment of mice bearing xenografts of the Caki-1 renal cell carcinoma, sensitive to AF in vitro, resulted in significant antitumor activity, including tumor-free survivors.
  • Studies in 13 renal cell strains isolated from patients with clear cell (9) or papillary (4) renal cell carcinoma indicated that 3 of 4 papillary strains were sensitive to AF compared with 2 of 9 clear cell strains.
  • CONCLUSIONS: AF has noteworthy antitumor activity against certain human tumor renal cell lines in vitro and in vivo, which correlates with drug metabolism to covalently binding metabolites after CYP1A1 and CYP1B1 gene expression.
  • AF sensitive renal cell strains are predominantly of the papillary histological type.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / enzymology. Cytochrome P-450 CYP1A1 / physiology. Flavonoids / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / enzymology
  • [MeSH-minor] Animals. Cell Division / drug effects. Drug Screening Assays, Antitumor. Humans. Mice. Neoplasm Transplantation. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017268.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-07002
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  •  go-up   go-down


21. Zhang J, Kang SK, Wang L, Touijer A, Hricak H: Distribution of renal tumor growth rates determined by using serial volumetric CT measurements. Radiology; 2009 Jan;250(1):137-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty-three of 2304 patients (34 men, 19 women; mean age, 67 years +/- 10 [standard deviation; range, 39-88 years) who underwent nephrectomy from 1989 to 2006 did not receive preoperative chemotherapy or radiation therapy and underwent at least two preoperative contrast material-enhanced CT examinations (at least 3 months apart) with identical section thickness that was no more than one-fifth of longitudinal tumor diameter.
  • Reciprocal of doubling time (DT) (RDT) was calculated.
  • RESULTS: Thirty-two clear cell carcinomas, 10 papillary carcinomas, six chromophobe carcinomas, four oncocytomas, and one angiomyolipoma were analyzed.
  • DT ranged from -78476.54 to 18057.43 days (mean, -1230.73 days; median, 590.51 days).
  • Age at diagnosis correlated negatively with renal tumor growth rate (P = .03).
  • [MeSH-major] Cone-Beam Computed Tomography / methods. Kidney Cortex / radiography. Kidney Neoplasms / radiography
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / radiography. Adenoma, Oxyphilic / surgery. Adult. Aged. Aged, 80 and over. Angiomyolipoma / pathology. Angiomyolipoma / radiography. Angiomyolipoma / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radiography. Carcinoma, Papillary / surgery. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / radiography. Carcinoma, Renal Cell / surgery. Disease Progression. Female. Humans. Male. Mathematical Computing. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Tumor Burden

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2009.
  • [CommentIn] Radiology. 2013 Dec;269(3):949-50 [24261507.001]
  • [CommentIn] Radiology. 2009 Jul;252(1):314; author reply 314-5 [19561267.001]
  • [ErratumIn] Radiology. 2013 Dec;269(3):950
  • [ErratumIn] Radiology. 2009 Jul;252(1):318
  • (PMID = 19092093.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Vezzadini C, Cremonini N, Sforza A, Presutti L, Chiarini V: Treated Wilm's tumor in childhood as potential risk factor for second thyroid cancer. Panminerva Med; 2002 Sep;44(3):275-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The potential risk of a treatment-induced second neoplasia affecting the thyroid is well known after radiation therapy for several types of cancer, but few cases have been related to incidental irradiation for Wilms' tumor.
  • We report a case of a papillary thyroid carcinoma discovered in a young patient 15 years after treatment of a Wilms' tumor.
  • His past medical history included at the age of 2 years surgical resection, chemotherapy (actinomycin-D and vincristine) and cesium radiation therapy to the right side for a Wilms' tumor in stage III: a total dose of 7700 rads was delivered to an area of 17 x 10 cm in the right flank.
  • After fine-needle demonstration of a follicular thyroid lesion, the patient underwent right lobectomy, followed by total thyroidectomy for histologic diagnosis of a follicular variant papillary cancer.
  • Residual thyroid tissue was ablated by iodine-131 administration (3700 MBq), but scanning after therapeutic iodine showed radioactive uptake in the left regional lymph nodes, with elevated serum thyroglobulin off therapy (830 ng/ml).
  • Magnetic resonance imaging confirmed the presence of lymph node enlargements and bilateral neck dissection was performed, followed by radioiodine treatment (3700 MBq) and thyroxine suppressive therapy.
  • [MeSH-major] Carcinoma, Papillary / etiology. Kidney Neoplasms / radiotherapy. Neoplasms, Radiation-Induced. Neoplasms, Second Primary / etiology. Thyroid Neoplasms / etiology. Wilms Tumor / radiotherapy
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Humans. Male. Risk Factors


23. Kauffman EC, Barocas DA, Chen YT, Yang XJ, Scherr DS, Tu JJ: Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes. J Urol; 2009 May;181(5):2305-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This problem is most notable for the chromophobe subtype of renal cell carcinoma, which can be histologically indistinguishable from oncocytoma with investigational molecular markers failing to provide reliable differentiation.
  • KAI1 is a metastasis suppressor gene whose expression correlates inversely with the metastatic potential of most solid tumor cancer types.
  • MATERIALS AND METHODS: Immunohistochemical staining for KAI1 protein was performed in 152 nephrectomy specimens, including 48 clear cell, 35 papillary and 31 chromophobe renal cell carcinoma samples, 28 oncocytomas and 10 tumor-free kidneys.
  • KAI1 mRNA levels were compared by quantitative reverse transcriptase-polymerase chain reaction in an additional 22 chromophobe renal cell carcinoma and oncocytoma samples.
  • RESULTS: In all 10 tumor-free kidneys KAI1 protein was detected exclusively in distal tubule cell membranes.
  • Of the tumor specimens KAI1 protein was absent in all papillary renal cell carcinoma specimens.
  • In contrast, 27 of 31 chromophobe renal cell carcinoma specimens (87%) expressed KAI1 protein, most at moderate or high levels.
  • The diagnostic accuracy of KAI1 immunostaining for discerning chromophobe renal cell carcinoma from oncocytoma was 90% with similar results observed at the RNA level.
  • CONCLUSIONS: KAI1 is an accurate biomarker for chromophobe renal cell carcinoma that may aid in the diagnostic differentiation of chromophobe renal cell carcinoma from oncocytoma.
  • It remains to be determined whether KAI1 expression contributes to the low metastatic potential of chromophobe renal cell carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Extracellular Matrix Proteins / metabolism. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biopsy, Needle. Case-Control Studies. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Nephrectomy. Prognosis. Reference Values. Risk Assessment. Sampling Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303095.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / KAL1 protein, human; 0 / Nerve Tissue Proteins
  •  go-up   go-down


24. Prager GW, Poettler M, Schmidinger M, Mazal PR, Susani M, Zielinski CC, Haitel A: CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest; 2009 Apr;39(4):304-10
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In a variety of malignant diseases, molecular targeting represents a therapeutic option, whereby, when compared with chemotherapy, fewer side effects are thought to be expected.
  • Especially in renal cell cancer (RCC), tyrosine kinase-inhibitors have been established as useful and highly effective therapy.
  • However, tyrosine kinase-inhibitors currently approved for RCC treatment lack single molecule specificity and bear a variety of side effects of the gastro-intestinal tract, skin, heart and haematopoietic system.
  • Therefore, the identification of novel cell surface markers is sought, which might lead to novel diagnostic and therapeutic strategies in cancer.
  • MATERIAL AND METHODS: Paraffin-embedded RCCs from a well characterized tissue bank were immunohistochemically quantified for embryonic transmembrane antigen CD98hc (SLC3A2) expression and semi-quantitative analyses were correlated with subtype or grade of differentiation.
  • RESULTS: We found increased CD98hc expression in different types of malign RCCs, among them clear cell (cc)RCC, papillary (p)RCC and chromophobe (ch)RCC, but lack of expression in the benign renal oncocytoma.
  • Furthermore, the more malignant type II pRCC significantly higher expressed CD98hc than the less malignant and more differentiated type I pRCC (type II 83.34%, type I 4.76% CD98hc positive, P < 0.00001; n = 51).
  • The established marker for type I pRCC, Cytokreatin 7, showed 95.24% expression in type I and 26.67% expression in type II pRCC (P < 0.00001, n = 51).
  • In pRCCs, CD98hc might represent a novel and reliable marker for type II pRCC.
  • [MeSH-major] Antigens, CD98 Heavy Chain / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292886.001).
  • [ISSN] 1365-2362
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD98 Heavy Chain; 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R, Boccon-Gibod L, Denoux Y, Ferlicot S, Forest E, Fromont G, Hintzy MC, Laghouati M, Sibony M, Tucker ML, Weber N, Teh BT, Vieillefond A: Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol; 2008 May;32(5):656-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis was performed by cytogenetic examination of fresh material and/or by immunochemistry with antibodies directed against the C-terminal part of transcription factor E3 (TFE3) and native transcription factor EB (TFEB) proteins.
  • Antibodies against CK7, CD10, vimentin, epithelial membrane antigen, AE1-AE3, E-cadherin, alpha-methylacyl-coenzyme A racemase, melan A, and HMB45 were tested on tissue microarrays.
  • Two patients had a previous history of chemotherapy and 1 had a history of renal failure.
  • Mixed papillary and nested patterns with clear and/or eosinophilic cells represented the most consistent histologic appearance, with common foci of calcifications regardless of the type of translocation.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Gene Expression Profiling. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / analysis. Biomarkers, Tumor / analysis. Child. Cytogenetic Analysis. Female. Gene Expression Regulation, Neoplastic. Genome. Humans. Infant. Male. Neoplasm Proteins / analysis. Nephrectomy. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344867.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / TFE3 protein, human; 0 / TFEB protein, human
  •  go-up   go-down


26. Tanaka K, Hara I, Takenaka A, Kawabata G, Fujisawa M: Incidence of local and port site recurrence of urologic cancer after laparoscopic surgery. Urology; 2008 Apr;71(4):728-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included 162 radical prostatectomies, 67 radical nephrectomies, 20 partial nephrectomies, 45 nephroureterectomies, 5 retroperitoneal lymph node dissections of testicular cancers after chemotherapy, 3 radical cystectomies, and 2 other procedures.
  • No patients without a histologic diagnosis of cancer were included in this study.
  • RESULTS: Of the 304 patients with cancer, 4 (1.3%) developed a local recurrence, including after retroperitoneal lymph node dissection in 2 patients, radical nephrectomy in 1, and radical cystectomy in 1.
  • The histologic type of both testicular cancers was mixed germ cell tumor, with one occurring in a renal hilar lymph node and the other in a paraaortic lymph node and kidney.
  • The histologic type of the renal cell carcinoma was papillary renal cell carcinoma with sarcomatoid features (Stage pT3aN1), and it occurred in a retrocaval lymph node.
  • The histologic type of the bladder cancer was transitional cell carcinoma, Grade 3, Stage pT4aN0, and it presented as peritoneal carcinomatosis 11 months postoperatively.
  • However, two recurrences were found in 5 patients who had undergone retroperitoneal lymph node dissection for testicular cancer after chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279936.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement